CN101631464A - 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 - Google Patents

用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 Download PDF

Info

Publication number
CN101631464A
CN101631464A CN200780044849A CN200780044849A CN101631464A CN 101631464 A CN101631464 A CN 101631464A CN 200780044849 A CN200780044849 A CN 200780044849A CN 200780044849 A CN200780044849 A CN 200780044849A CN 101631464 A CN101631464 A CN 101631464A
Authority
CN
China
Prior art keywords
yl
methoxy
dihydro
imidazo
quinazolin
Prior art date
Application number
CN200780044849A
Other languages
English (en)
Chinese (zh)
Inventor
M·亨特曼
J·伍德
W·斯科特
M·米歇尔斯
A-M·坎贝尔
A-M·比利翁
R·B·罗利
A·雷德曼
Original Assignee
拜耳先灵医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US87309006P priority Critical
Priority to US60/873,090 priority
Application filed by 拜耳先灵医药股份有限公司 filed Critical 拜耳先灵医药股份有限公司
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39492563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101631464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of CN101631464A publication Critical patent/CN101631464A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
CN200780044849A 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 CN101631464A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US87309006P true 2006-12-05 2006-12-05
US60/873,090 2006-12-05

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810535933.9A CN108774232A (zh) 2006-12-05 2007-12-05 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN201510632842.3A CN105254634A (zh) 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810535933.9A Division CN108774232A (zh) 2006-12-05 2007-12-05 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Publications (1)

Publication Number Publication Date
CN101631464A true CN101631464A (zh) 2010-01-20

Family

ID=39492563

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201510632842.3A CN105254634A (zh) 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN200780044849A CN101631464A (zh) 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物
CN201810535933.9A CN108774232A (zh) 2006-12-05 2007-12-05 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201510632842.3A CN105254634A (zh) 2006-12-05 2007-12-05 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810535933.9A CN108774232A (zh) 2006-12-05 2007-12-05 2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Country Status (41)

Country Link
US (3) USRE46856E1 (und)
EP (1) EP2096919B1 (und)
JP (1) JP5326092B2 (und)
KR (1) KR101501785B1 (und)
CN (3) CN105254634A (und)
AR (1) AR064106A1 (und)
AU (1) AU2007328008B2 (und)
BR (1) BRPI0720178B1 (und)
CA (1) CA2671614C (und)
CL (1) CL2007003508A1 (und)
CO (1) CO6220908A2 (und)
CR (1) CR10838A (und)
CU (1) CU23796B7 (und)
DK (1) DK2096919T3 (und)
DO (1) DOP2009000135A (und)
EA (1) EA018839B1 (und)
EC (1) ECSP099387A (und)
ES (1) ES2572189T3 (und)
GT (1) GT200900154A (und)
HK (1) HK1217953A1 (und)
HN (1) HN2009001131A (und)
HU (1) HUE028773T2 (und)
IL (1) IL198273A (und)
JO (1) JO3147B1 (und)
MA (1) MA31283B1 (und)
MX (1) MX2009006001A (und)
MY (1) MY157944A (und)
NO (1) NO342348B1 (und)
NZ (1) NZ577342A (und)
PA (1) PA8759601A1 (und)
PE (1) PE14442008A1 (und)
RS (1) RS56045B1 (und)
SG (1) SG177170A1 (und)
SI (1) SI2096919T1 (und)
SV (1) SV2009003288A (und)
TN (1) TN2009000137A1 (und)
TW (1) TWI406662B (und)
UA (1) UA96965C2 (und)
UY (1) UY30761A1 (und)
WO (1) WO2008070150A1 (und)
ZA (1) ZA200904691B (und)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906094A (zh) * 2010-11-11 2013-01-30 拜耳知识产权有限责任公司 用于治疗过度增殖性病症和与血管发生相关的疾病的氨基醇取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物
CN103214489A (zh) * 2013-02-25 2013-07-24 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103608018A (zh) * 2011-04-05 2014-02-26 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉的用途
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN104557955A (zh) * 2013-10-23 2015-04-29 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105263497A (zh) * 2013-04-08 2016-01-20 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
CN105934256A (zh) * 2013-12-03 2016-09-07 拜耳制药股份公司 Pi3k-抑制剂的组合产品
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
CN107278204A (zh) * 2014-11-07 2017-10-20 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009091550A2 (en) * 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
EP2184276A1 (en) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
WO2010082627A1 (ja) 2009-01-16 2010-07-22 ダイソー株式会社 2-ヒドロキシメチルモルホリン塩の製造方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112012026480A2 (pt) 2010-04-16 2016-08-16 Bayer Ip Gmbh combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101898610B1 (ko) 2010-08-31 2018-09-14 서울대학교산학협력단 PPARδ 활성물질의 태자 재프로그래밍 용도
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
AU2014354769A1 (en) * 2013-11-26 2016-05-26 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
EP3077003A1 (en) 2013-12-03 2016-10-12 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
TWI533869B (zh) 2014-03-11 2016-05-21 Univ Nat Central 蒽醌[2,1-c][1,2,5]噻二唑-6,11-二酮化合物緩解疼痛的應用
TWI533871B (zh) 2014-03-11 2016-05-21 Univ Nat Central 萘并[2,3-f]喹喔啉-7,12-二酮化合物緩解疼痛的應用
FR3018813B1 (fr) * 2014-03-18 2016-04-15 Maco Pharma Sa Procede de synthese d'un derive de psoralene
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
SG11201707239WA (en) * 2015-03-09 2017-10-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP3268490A1 (en) 2015-03-09 2018-01-17 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3426657A1 (en) 2016-03-08 2019-01-16 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN108368117A (en) * 2016-06-08 2018-08-03 深圳市塔吉瑞生物医药有限公司 A kind of substituted imidazolo-quinazoline compounds and its pharmaceutical composition
US20190255063A1 (en) 2016-09-23 2019-08-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2018153980A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
WO2019048527A1 (en) 2017-09-08 2019-03-14 Bayer Pharma Aktiengesellschaft Formulations of copanlisib
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
DK1549652T3 (da) * 2002-09-30 2009-02-23 Bayer Healthcare Ag Kondenserede azolpyrimidinderivater
AT412873B (de) 2004-02-20 2005-08-25 Aop Orphan Pharmaceuticals Ag Verfahren zur herstellung von anagrelid hydrochlorid
WO2007143483A2 (en) 2006-06-01 2007-12-13 Smithkline Beecham Corporation Combination of pazopanib and lapatinib for treating cancer
WO2008002039A1 (en) 2006-06-28 2008-01-03 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting the growth of cancer cell
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN103339133B (zh) * 2010-11-11 2016-06-15 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103339133A (zh) * 2010-11-11 2013-10-02 拜耳知识产权有限责任公司 烷氧基取代的2,3-二氢咪唑并[1,2-c]喹唑啉
CN103370320A (zh) * 2010-11-11 2013-10-23 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
CN102906094A (zh) * 2010-11-11 2013-01-30 拜耳知识产权有限责任公司 用于治疗过度增殖性病症和与血管发生相关的疾病的氨基醇取代的2,3-二氢咪唑并[1,2-c]喹唑啉衍生物
CN103608018A (zh) * 2011-04-05 2014-02-26 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉的用途
US10202385B2 (en) 2011-04-05 2019-02-12 Bayer Intellectual Property Gmbh Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines
TWI549954B (zh) * 2011-04-05 2016-09-21 Bayer Ip Gmbh 經取代之2,3-二氫咪唑并[1,2-c]喹唑啉鹽
CN103649091A (zh) * 2011-04-05 2014-03-19 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN103649091B (zh) * 2011-04-05 2016-06-22 拜耳知识产权有限责任公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US10300143B2 (en) 2012-06-15 2019-05-28 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CN103214489A (zh) * 2013-02-25 2013-07-24 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
CN105263497A (zh) * 2013-04-08 2016-01-20 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
CN105263497B (zh) * 2013-04-08 2019-04-30 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
CN104557955A (zh) * 2013-10-23 2015-04-29 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途
CN104557955B (zh) * 2013-10-23 2017-05-03 上海汇伦生命科技有限公司 作为PI3K/mTOR抑制剂的三环类化合物,其制备方法和用途
CN105934256A (zh) * 2013-12-03 2016-09-07 拜耳制药股份公司 Pi3k-抑制剂的组合产品
CN107278204A (zh) * 2014-11-07 2017-10-20 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
CN107074776A (zh) * 2014-11-07 2017-08-18 拜耳制药股份公司 Copanlisib及其二盐酸盐的合成
CN105130997A (zh) * 2015-09-25 2015-12-09 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998A (zh) * 2015-09-25 2015-12-09 苏州立新制药有限公司 库潘尼西的制备方法
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
HN2009001131A (es) 2012-02-06
TW200840582A (en) 2008-10-16
MX2009006001A (es) 2009-06-16
US20110083984A1 (en) 2011-04-14
SG177170A1 (en) 2012-01-30
AR064106A1 (es) 2009-03-11
EA018839B1 (ru) 2013-11-29
MA31283B1 (fr) 2010-04-01
GT200900154A (es) 2012-01-17
USRE46856E1 (en) 2018-05-22
WO2008070150A1 (en) 2008-06-12
PE14442008A1 (es) 2008-11-29
NO20092529L (no) 2009-08-27
RS56045B1 (sr) 2017-09-29
EP2096919B1 (en) 2016-03-02
ES2572189T3 (es) 2016-05-30
SV2009003288A (es) 2009-10-02
CA2671614C (en) 2016-01-26
IL198273D0 (en) 2009-12-24
CU23796B7 (es) 2012-03-15
TN2009000137A1 (en) 2010-10-18
DK2096919T3 (en) 2016-05-17
EP2096919A4 (en) 2010-11-17
HK1217953A1 (zh) 2017-01-27
MY157944A (en) 2016-08-30
JP5326092B2 (ja) 2013-10-30
AU2007328008A1 (en) 2008-06-12
ECSP099387A (es) 2009-11-30
JP2010511718A (ja) 2010-04-15
US20130261113A1 (en) 2013-10-03
KR101501785B1 (ko) 2015-03-11
CL2007003508A1 (es) 2008-07-04
CR10838A (es) 2009-11-05
EA200900733A1 (ru) 2009-12-30
IL198273A (en) 2015-07-30
NO342348B1 (no) 2018-05-07
BRPI0720178A2 (pt) 2013-12-24
DOP2009000135A (es) 2009-06-30
BRPI0720178B1 (pt) 2019-04-09
CN105254634A (zh) 2016-01-20
NZ577342A (en) 2012-01-12
US8466283B2 (en) 2013-06-18
CN108774232A (zh) 2018-11-09
PA8759601A1 (es) 2009-02-09
HUE028773T2 (en) 2017-01-30
TWI406662B (zh) 2013-09-01
SI2096919T1 (sl) 2016-06-30
AU2007328008B2 (en) 2014-03-13
CU20090103A7 (es) 2011-12-28
ZA200904691B (en) 2010-09-29
UY30761A1 (es) 2008-07-03
KR20090096440A (ko) 2009-09-10
JO3147B1 (ar) 2017-09-20
EP2096919A1 (en) 2009-09-09
CA2671614A1 (en) 2008-06-12
UA96965C2 (ru) 2011-12-26
CO6220908A2 (es) 2010-11-19

Similar Documents

Publication Publication Date Title
CN101365454B (zh) 取代的4-氨基-吡咯并三嗪衍生物
JP5249776B2 (ja) 過剰増殖性疾患および血管新生と関連する疾患を処置するために有用な置換された4−アミノ−ピロロトリアジン誘導体
JP5728683B2 (ja) チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
US9676766B2 (en) Triazolopyridines
CN102413831B (zh) 取代的咪唑并喹喔啉
US10266548B2 (en) Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases
DK2694508T3 (en) Substituted 2,3-dihydroimidazo [1,2-c] QUINAZOLINSALTE
TW200909428A (en) Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2507233B1 (en) Substituted triazolopyridines
KR20070102693A (ko) 피리도(3,2-d)피리미딘 및 의학 치료에 유용한 이것의약학적 조성물
KR101501785B1 (ko) 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린 유도체
CN106220623A (zh) 用于激酶调节的化合物和方法及其适应症
JP5805654B2 (ja) トリアゾロピリジン誘導体
JP6121991B2 (ja) Mknk1キナーゼ阻害剤としてのアミノ置換イミダゾピリダジン
EP2758401B1 (en) Amino-substituted imidazopyridazines
EP2614063B1 (en) Substituted imidazopyridazines
EP2651944B1 (en) Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP6174586B2 (ja) 置換イミダゾピリダジン
US9382255B2 (en) Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors
EP2723748B1 (en) Heterocyclyl aminoimidazopyridazines
EP2834245B1 (en) Amino-substituted imidazopyridazines
US20140187548A1 (en) 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2858993B1 (en) Amino-substituted imidazopyridazines
US20160311833A1 (en) Novel indazolecarboxamides, processes for their preparation, pharmaceutical preparations comprising them and their use for producing medicaments
WO2014095774A1 (de) Bet-proteininhibitorische dihydropyridopyrazinone

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1139839

Country of ref document: HK

C53 Correction of patent for invention or patent application
COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING AG TO: BAYER PHARMA AG

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMA AG

Effective date: 20130805

C41 Transfer of patent application or patent right or utility model